{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:27:58Z","timestamp":1772166478748,"version":"3.50.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"French National Research Agency \u00ab Investissements d'avenir \u00bb program","award":["ANR-15-IDEX-02"],"award-info":[{"award-number":["ANR-15-IDEX-02"]}]},{"name":"French National Research Agency \u00ab Investissements d'avenir \u00bb program","award":["ANR-15-IDEX-02"],"award-info":[{"award-number":["ANR-15-IDEX-02"]}]},{"name":"French National Research Agency \u00ab Investissements d'avenir \u00bb program","award":["ANR-15-IDEX-02"],"award-info":[{"award-number":["ANR-15-IDEX-02"]}]},{"name":"French National Research Agency \u00ab CBH-EUR-GS \u00bb program","award":["ANR-17-EURE-0003"],"award-info":[{"award-number":["ANR-17-EURE-0003"]}]},{"name":"French National Research Agency \u00ab CBH-EUR-GS \u00bb program","award":["ANR-17-EURE-0003"],"award-info":[{"award-number":["ANR-17-EURE-0003"]}]},{"name":"French National Research Agency \u00ab CBH-EUR-GS \u00bb program","award":["ANR-17-EURE-0003"],"award-info":[{"award-number":["ANR-17-EURE-0003"]}]},{"DOI":"10.13039\/100030971","name":"Centre Hospitalier, Universit\u00e9 Grenoble Alpes","doi-asserted-by":"publisher","award":["EPIC-AO2021"],"award-info":[{"award-number":["EPIC-AO2021"]}],"id":[{"id":"10.13039\/100030971","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030971","name":"Centre Hospitalier, Universit\u00e9 Grenoble Alpes","doi-asserted-by":"publisher","award":["LYMPHOBET2-38RC20.076"],"award-info":[{"award-number":["LYMPHOBET2-38RC20.076"]}],"id":[{"id":"10.13039\/100030971","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030971","name":"Centre Hospitalier, Universit\u00e9 Grenoble Alpes","doi-asserted-by":"publisher","award":["EPIC-AO2021"],"award-info":[{"award-number":["EPIC-AO2021"]}],"id":[{"id":"10.13039\/100030971","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030971","name":"Centre Hospitalier, Universit\u00e9 Grenoble Alpes","doi-asserted-by":"publisher","award":["LYMPHOBET2-38RC20.076"],"award-info":[{"award-number":["LYMPHOBET2-38RC20.076"]}],"id":[{"id":"10.13039\/100030971","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030971","name":"Centre Hospitalier, Universit\u00e9 Grenoble Alpes","doi-asserted-by":"publisher","award":["A02022"],"award-info":[{"award-number":["A02022"]}],"id":[{"id":"10.13039\/100030971","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030971","name":"Centre Hospitalier, Universit\u00e9 Grenoble Alpes","doi-asserted-by":"publisher","award":["LYMPHOBET2-38RC20.076"],"award-info":[{"award-number":["LYMPHOBET2-38RC20.076"]}],"id":[{"id":"10.13039\/100030971","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Aramis, oncohematology patient organization"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"DOI":"10.1186\/s13148-024-01788-7","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T13:34:02Z","timestamp":1734615242000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["BET inhibition revealed varying MYC dependency mechanisms independent of gene alterations in aggressive B-cell lymphomas"],"prefix":"10.1186","volume":"16","author":[{"given":"Loris","family":"Delrieu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sieme","family":"Hamaidia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Montaut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Cecilia","family":"Garcia-Sandoval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Teste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Betton-Fraisse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Bonnefoix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Carras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9my","family":"Gressin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Govin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anouk","family":"Emadali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"issue":"20","key":"1788_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"issue":"1","key":"1788_CR2","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/imr.12734","volume":"288","author":"A Bisso","year":"2019","unstructured":"Bisso A, Sab\u00f2 A, Amati B. MYC in Germinal Center-derived lymphomas: mechanisms and therapeutic opportunities. Immunol Rev. 2019;288(1):178\u201397.","journal-title":"Immunol Rev"},{"issue":"1","key":"1788_CR3","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1182\/asheducation-2013.1.575","volume":"2013","author":"G Ott","year":"2013","unstructured":"Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Hematology. 2013;2013(1):575\u201383. https:\/\/doi.org\/10.1182\/asheducation-2013.1.575.","journal-title":"Hematology"},{"issue":"6","key":"1788_CR4","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1159\/000505892","volume":"143","author":"Y Xia","year":"2020","unstructured":"Xia Y, Zhang X. The spectrum of MYC alterations in diffuse large B-cell lymphoma. Acta Haematol. 2020;143(6):520\u20138.","journal-title":"Acta Haematol"},{"issue":"15","key":"1788_CR5","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.1016\/S1470-2045(15)00005-4","volume":"16","author":"C Sarkozy","year":"2015","unstructured":"Sarkozy C, Traverse-Glehen A, Coiffier B. Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas. Lancet Oncol. 2015;16(15):e555\u201367.","journal-title":"Lancet Oncol"},{"issue":"18","key":"1788_CR6","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1182\/blood-2017-12-820605","volume":"131","author":"DW Scott","year":"2018","unstructured":"Scott DW, King RL, Staiger AM, Ben-Neriah S, Jiang A, Horn H, et al. High-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood. 2018;131(18):2060\u20134.","journal-title":"Blood"},{"key":"1788_CR7","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E, et al. (2022). The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 36(7):1720\u201148."},{"issue":"3","key":"1788_CR8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.18.01583","volume":"37","author":"D Ennishi","year":"2019","unstructured":"Ennishi D, Jiang A, Boyle M, Collinge B, Grande BM, Ben-Neriah S, et al. Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(3):190\u2013201.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1788_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41392-021-00500-y","volume":"6","author":"C Wang","year":"2021","unstructured":"Wang C, Zhang J, Yin J, Gan Y, Xu S, Gu Y, et al. Alternative approaches to target Myc for cancer treatment. Signal Transduct Target Ther. 2021;6(1):117.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"1788_CR10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41573-019-0030-7","volume":"18","author":"AG Cochran","year":"2019","unstructured":"Cochran AG, Conery AR, Sims RJ. Bromodomains: a new target class for drug development. Nat Rev Drug Discov. 2019;18(8):609\u201328.","journal-title":"Nat Rev Drug Discov"},{"issue":"7327","key":"1788_CR11","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067\u201373.","journal-title":"Nature"},{"issue":"7327","key":"1788_CR12","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/nature09589","volume":"468","author":"E Nicodeme","year":"2010","unstructured":"Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, wa Chung C, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468(7327):1119\u201323.","journal-title":"Nature"},{"issue":"5","key":"1788_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nrd4286","volume":"13","author":"P Filippakopoulos","year":"2014","unstructured":"Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov. 2014;13(5):337\u201356.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"1788_CR14","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904\u201317.","journal-title":"Cell"},{"issue":"40","key":"1788_CR15","doi-asserted-by":"publisher","first-page":"16669","DOI":"10.1073\/pnas.1108190108","volume":"108","author":"JA Mertz","year":"2011","unstructured":"Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA. 2011;108(40):16669\u201374.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"1788_CR16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","volume":"153","author":"J Lov\u00e9n","year":"2013","unstructured":"Lov\u00e9n J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153(2):320\u201334.","journal-title":"Cell"},{"issue":"6","key":"1788_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ccr.2013.11.003","volume":"24","author":"B Chapuy","year":"2013","unstructured":"Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MGM, Qi J, et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell. 2013;24(6):777\u201390.","journal-title":"Cancer Cell"},{"issue":"7","key":"1788_CR18","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1158\/1078-0432.CCR-14-1561","volume":"21","author":"M Boi","year":"2015","unstructured":"Boi M, Gaudio E, Bonetti P, Kwee I, Bernasconi E, Tarantelli C, et al. The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs. Clin Cancer Res. 2015;21(7):1628\u201338.","journal-title":"Clin Cancer Res"},{"issue":"31","key":"1788_CR19","doi-asserted-by":"publisher","first-page":"11365","DOI":"10.1073\/pnas.1411701111","volume":"111","author":"M Ceribelli","year":"2014","unstructured":"Ceribelli M, Kelly PN, Shaffer AL, Wright GW, Xiao W, Yang Y, et al. Blockade of oncogenic I\u03baB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci. 2014;111(31):11365\u201370.","journal-title":"Proc Natl Acad Sci"},{"issue":"14","key":"1788_CR20","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1182\/bloodadvances.2020002231","volume":"4","author":"TEC Cummin","year":"2020","unstructured":"Cummin TEC, Cox KL, Murray TD, Turaj AH, Dunning L, English VL, et al. BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression. Blood Adv. 2020;4(14):3316\u201328.","journal-title":"Blood Adv"},{"issue":"14","key":"1788_CR21","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1038\/s41388-017-0111-1","volume":"37","author":"A Esteve-Arenys","year":"2018","unstructured":"Esteve-Arenys A, Valero JG, Chamorro-Jorganes A, Gonzalez D, Rodriguez V, Dlouhy I, et al. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1\/A1 in in vitro and in vivo models of MYC+\/BCL2+ double hit lymphoma. Oncogene. 2018;37(14):1830\u201344.","journal-title":"Oncogene"},{"issue":"9","key":"1788_CR22","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1158\/1535-7163.MCT-15-0924","volume":"15","author":"SJ Hogg","year":"2016","unstructured":"Hogg SJ, Newbold A, Vervoort SJ, Cluse LA, Martin BP, Gregory GP, et al. BET inhibition induces apoptosis in aggressive B-cell lymphoma via epigenetic regulation of BCL-2 family members. Mol Cancer Ther. 2016;15(9):2030\u201341.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1788_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-019-0761-2","volume":"12","author":"W Li","year":"2019","unstructured":"Li W, Gupta SK, Han W, Kundson RA, Nelson S, Knutson D, et al. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with epigenetic bromodomain inhibitors. J Hematol OncolJ Hematol Oncol. 2019;12(1):73.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"1","key":"1788_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1158\/1078-0432.CCR-13-3346","volume":"21","author":"SE Trabucco","year":"2015","unstructured":"Trabucco SE, Gerstein RM, Evens AM, Bradner JE, Shultz LD, Greiner DL, et al. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin Cancer Res. 2015;21(1):113\u2013224.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1788_CR25","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","volume":"124","author":"T Shorstova","year":"2021","unstructured":"Shorstova T, Foulkes WD, Witcher M. Achieving clinical success with BET inhibitors as anti-cancer agents. Br J Cancer. 2021;124(9):1478\u201390.","journal-title":"Br J Cancer"},{"issue":"7794","key":"1788_CR26","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41586-020-1930-8","volume":"578","author":"EJ Faivre","year":"2020","unstructured":"Faivre EJ, McDaniel KF, Albert DH, Mantena SR, Plotnik JP, Wilcox D, et al. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer. Nature. 2020;578(7794):306\u201310.","journal-title":"Nature"},{"issue":"6489","key":"1788_CR27","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1126\/science.aaz8455","volume":"368","author":"O Gilan","year":"2020","unstructured":"Gilan O, Rioja I, Knezevic K, Bell MJ, Yeung MM, Harker NR, et al. Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Science. 2020;368(6489):387\u201394.","journal-title":"Science"},{"issue":"1","key":"1788_CR28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1073\/pnas.97.1.309","volume":"97","author":"MB Callanan","year":"2000","unstructured":"Callanan MB, Le Baccon P, Mossuz P, Duley S, Bastard C, Hamoudi R, et al. The IgG Fc receptor, FcgammaRIIB, is a target for deregulation by chromosomal translocation in malignant lymphoma. Proc Natl Acad Sci USA. 2000;97(1):309\u201314.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1788_CR29","unstructured":"ISCN 2020 | Karger Book [Internet]. [cit\u00e9 12 janv 2023]. Disponible sur: https:\/\/www.karger.com\/Book\/Home\/279152"},{"issue":"10","key":"1788_CR30","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1093\/bioinformatics\/btac166","volume":"38","author":"GH Putri","year":"2022","unstructured":"Putri GH, Anders S, Pyl PT, Pimanda JE, Zanini F. Analysing high-throughput sequencing data in Python with HTSeq 2.0. Bioinformatics. 2022;38(10):2943\u20135.","journal-title":"Bioinformatics"},{"issue":"12","key":"1788_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):1\u201321.","journal-title":"Genome Biol"},{"issue":"43","key":"1788_CR32","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"1788_CR33","first-page":"100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation. 2021;2(3):100141.","journal-title":"Innovation"},{"issue":"8","key":"1788_CR34","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/ncb1618","volume":"9","author":"A Zippo","year":"2007","unstructured":"Zippo A, De Robertis A, Serafini R, Oliviero S. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol. 2007;9(8):932\u201344.","journal-title":"Nat Cell Biol"},{"issue":"3","key":"1788_CR35","doi-asserted-by":"publisher","first-page":"498","DOI":"10.4161\/cc.8.3.7701","volume":"8","author":"D Wiederschain","year":"2009","unstructured":"Wiederschain D, Wee S, Chen L, Loo A, Yang G, Huang A, et al. Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle Georget Tex. 2009;8(3):498\u2013504.","journal-title":"Cell Cycle Georget Tex."},{"issue":"8","key":"1788_CR36","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/emmm.201202034","volume":"5","author":"A Emadali","year":"2013","unstructured":"Emadali A, Rousseaux S, Bruder-Costa J, Rome C, Duley S, Hamaidia S, et al. Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers. EMBO Mol Med. 2013;5(8):1180\u201395.","journal-title":"EMBO Mol Med"},{"issue":"W1","key":"1788_CR37","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50(W1):W739\u201343. https:\/\/doi.org\/10.1093\/nar\/gkac382.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"1788_CR38","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B-cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679\u201390.","journal-title":"Nat Med"},{"issue":"2","key":"1788_CR39","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","volume":"171","author":"A Reddy","year":"2017","unstructured":"Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171(2):481-494.e15.","journal-title":"Cell"},{"issue":"9","key":"1788_CR40","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.4161\/cc.3.9.1145","volume":"3","author":"RC Sears","year":"2004","unstructured":"Sears RC. The life cycle of C-Myc: from synthesis to degradation. Cell Cycle. 2004;3(9):1131\u20135. https:\/\/doi.org\/10.4161\/cc.3.9.1145.","journal-title":"Cell Cycle"},{"issue":"49","key":"1788_CR41","doi-asserted-by":"publisher","first-page":"19754","DOI":"10.1073\/pnas.1310658110","volume":"110","author":"S Picaud","year":"2013","unstructured":"Picaud S, Wells C, Felletar I, Brotherton D, Martin S, Savitsky P, et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci. 2013;110(49):19754\u20139.","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"1788_CR42","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2015.07.013","volume":"162","author":"HW Park","year":"2015","unstructured":"Park HW, Kim YC, Yu B, Moroishi T, Mo JS, Plouffe SW, et al. Alternative Wnt signaling activates YAP\/TAZ. Cell. 2015;162(4):780\u201394.","journal-title":"Cell"},{"issue":"9","key":"1788_CR43","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1016\/j.celrep.2018.04.113","volume":"23","author":"S Samanta","year":"2018","unstructured":"Samanta S, Guru S, Elaimy AL, Amante JJ, Ou J, Yu J, et al. IMP3 stabilization of WNT5B mRNA facilitates TAZ activation in breast cancer. Cell Rep. 2018;23(9):2559\u201367.","journal-title":"Cell Rep"},{"issue":"3","key":"1788_CR44","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","volume":"26","author":"CI Bliss","year":"1939","unstructured":"Bliss CI. The toxicity of poisons applied jointly. Ann Appl Biol. 1939;26(3):585\u2013615.","journal-title":"Ann Appl Biol"},{"issue":"16","key":"1788_CR45","first-page":"2196","volume":"137","author":"B Collinge","year":"2021","unstructured":"Collinge B, Ben-Neriah S, Chong L, Boyle M, Jiang A, Miyata-Takata T, et al. The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. Blood. 2021;137(16):2196\u2013208.","journal-title":"Blood"},{"key":"1788_CR46","doi-asserted-by":"publisher","first-page":"5943","DOI":"10.2147\/OTT.S100515","volume":"9","author":"SM Abedin","year":"2016","unstructured":"Abedin SM, Boddy CS, Munshi HG. BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects. Onco Target Ther. 2016;9:5943\u201353.","journal-title":"Onco Target Ther."},{"issue":"4","key":"1788_CR47","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(16)00021-1","volume":"3","author":"S Amorim","year":"2016","unstructured":"Amorim S, Stathis A, Gleeson M, Iyengar S, Magarotto V, Leleu X, et al. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol. 2016;3(4):e196-204.","journal-title":"Lancet Haematol."},{"issue":"8","key":"1788_CR48","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1158\/2767-9764.CRC-22-0060","volume":"2","author":"KA Blum","year":"2022","unstructured":"Blum KA, Supko JG, Maris MB, Flinn IW, Goy A, Younes A, et al. A phase I study of pelabresib (CPI-0610), a small-molecule inhibitor of BET proteins, in patients with relapsed or refractory lymphoma. Cancer Res Commun. 2022;2(8):795\u2013805.","journal-title":"Cancer Res Commun."},{"issue":"6","key":"1788_CR49","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1158\/1078-0432.CCR-18-4071","volume":"26","author":"G Falchook","year":"2020","unstructured":"Falchook G, Rosen S, LoRusso P, Watts J, Gupta S, Coombs CC, et al. Development of 2 bromodomain and extraterminal inhibitors with distinct pharmacokinetic and pharmacodynamic profiles for the treatment of advanced malignancies. Clin Cancer Res. 2020;26(6):1247\u201357.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1788_CR50","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.annonc.2020.03.294","volume":"31","author":"V Moreno","year":"2020","unstructured":"Moreno V, Sepulveda JM, Vieito M, Hern\u00e1ndez-Guerrero T, Doger B, Saavedra O, et al. Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed\/refractory non-Hodgkin\u2019s lymphoma. Ann Oncol. 2020;31(6):780\u20138.","journal-title":"Ann Oncol"},{"issue":"1","key":"1788_CR51","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/s41467-023-36976-1","volume":"14","author":"V Moreno","year":"2023","unstructured":"Moreno V, Vieito M, Sepulveda JM, Galvao V, Hern\u00e1ndez-Guerrero T, Doger B, et al. BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas. Nat Commun. 2023;14(1):1359.","journal-title":"Nat Commun"},{"key":"1788_CR52","doi-asserted-by":"crossref","unstructured":"Zhang C, Stelloo E, Barrans S, Cucco F, Jiang D, Tzioni MM, et al. (2024). Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential. Leukemia. 1\u20119.","DOI":"10.1038\/s41375-023-02134-1"},{"issue":"28","key":"1788_CR53","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","volume":"30","author":"NA Johnson","year":"2012","unstructured":"Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-Cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1788_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-016-0278-3","volume":"7","author":"S Alghamdi","year":"2016","unstructured":"Alghamdi S, Khan I, Beeravolu N, McKee C, Thibodeau B, Wilson G, et al. BET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells. Stem Cell Res Ther. 2016;7(1):1\u201316.","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"1788_CR55","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.ajpath.2018.02.006","volume":"188","author":"JO Russell","year":"2018","unstructured":"Russell JO, Ko S, Saggi HS, Singh S, Poddar M, Shin D, et al. Bromodomain and extraterminal (BET) proteins regulate hepatocyte proliferation in hepatocyte-driven liver regeneration. Am J Pathol. 2018;188(6):1389\u2013405.","journal-title":"Am J Pathol"},{"issue":"5","key":"1788_CR56","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1021\/acs.chemrestox.7b00346","volume":"31","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Tian S, Xiong J, Zhou Y, Song H, Liu C. JQ-1 inhibits colon cancer proliferation via suppressing Wnt\/\u03b2-catenin signaling and miR-21. Chem Res Toxicol. 2018;31(5):302\u20137.","journal-title":"Chem Res Toxicol"},{"key":"1788_CR57","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ejphar.2019.03.018","volume":"852","author":"H Song","year":"2019","unstructured":"Song H, Shi L, Xu Y, Xu T, Fan R, Cao M, et al. BRD4 promotes the stemness of gastric cancer cells via attenuating miR-216a-3p-mediated inhibition of Wnt\/\u03b2-catenin signaling. Eur J Pharmacol. 2019;852:189\u201397.","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"1788_CR58","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/s41419-020-03117-1","volume":"11","author":"T Tian","year":"2020","unstructured":"Tian T, Guo T, Zhen W, Zou J, Li F. BET degrader inhibits tumor progression and stem-like cell growth via Wnt\/\u03b2-catenin signaling repression in glioma cells. Cell Death Dis. 2020;11(10):900.","journal-title":"Cell Death Dis"},{"issue":"7570","key":"1788_CR59","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature14898","volume":"525","author":"P Rathert","year":"2015","unstructured":"Rathert P, Roth M, Neumann T, Muerdter F, Roe JS, Muhar M, et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature. 2015;525(7570):543\u20137.","journal-title":"Nature"},{"issue":"7570","key":"1788_CR60","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature14888","volume":"525","author":"CY Fong","year":"2015","unstructured":"Fong CY, Gilan O, Lam EYN, Rubin AF, Ftouni S, Tyler D, et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature. 2015;525(7570):538\u201342.","journal-title":"Nature"},{"issue":"3","key":"1788_CR61","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/ng.3228","volume":"47","author":"A Keren-Paz","year":"2015","unstructured":"Keren-Paz A, Emmanuel R, Samuels Y. YAP and the drug resistance highway. Nat Genet. 2015;47(3):193\u20134.","journal-title":"Nat Genet"},{"key":"1788_CR62","first-page":"188341","volume":"1873","author":"F Reggiani","year":"2020","unstructured":"Reggiani F, Gobbi G, Ciarrocchi A, Ambrosetti DC, Sancisi V. Multiple roles and context-specific mechanisms underlying YAP and TAZ-mediated resistance to anti-cancer therapy. Biochim Biophys Acta BBA\u2014Rev Cancer. 2020;1873:188341.","journal-title":"Biochim Biophys Acta BBA\u2014Rev Cancer"},{"issue":"42","key":"1788_CR63","doi-asserted-by":"publisher","first-page":"6801","DOI":"10.1038\/s41388-019-0924-1","volume":"38","author":"G Gobbi","year":"2019","unstructured":"Gobbi G, Donati B, Do Valle IF, Reggiani F, Torricelli F, Remondini D, et al. The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells. Oncogene. 2019;38(42):6801\u201317.","journal-title":"Oncogene"},{"issue":"10","key":"1788_CR64","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-018-0158-8","volume":"24","author":"F Zanconato","year":"2018","unstructured":"Zanconato F, Battilana G, Forcato M, Filippi L, Azzolin L, Manfrin A, et al. Transcriptional addiction in cancer cells is mediated by YAP\/TAZ through BRD4. Nat Med. 2018;24(10):1599\u2013610.","journal-title":"Nat Med"},{"issue":"12","key":"1788_CR65","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.bbagrm.2016.10.001","volume":"1859","author":"Q Duan","year":"2016","unstructured":"Duan Q, Xiao Y, Zhu L, Liu Z, Mao X, Zhou Z, et al. BET bromodomain is a novel regulator of TAZ and its activity. Biochim Biophys Acta. 2016;1859(12):1527\u201337.","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"1788_CR66","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1002\/1878-0261.12667","volume":"14","author":"S Song","year":"2020","unstructured":"Song S, Li Y, Xu Y, Ma L, Pool Pizzi M, Jin J, et al. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma. Mol Oncol. 2020;14(6):1410\u201326.","journal-title":"Mol Oncol"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-024-01788-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-024-01788-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-024-01788-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T15:03:22Z","timestamp":1734620602000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-024-01788-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1788"],"URL":"https:\/\/doi.org\/10.1186\/s13148-024-01788-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4647617\/v1","asserted-by":"object"}]},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"27 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Non-applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Non-applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}